Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings

Date
2021
Author
Oral, Elif A.
Akinci, Baris
Subauste, Angela
Ajluni, Nevin
Esfandiari, Nazanene H.
Meral, Rasimcan
Neidert, Adam H.
Burant, Charles L.
Eraslan, Akin
Hench, Rita
Rus, Diana
Mckenna, Barbara
Hussain, Hero K.
Chenevert, Thomas L.
Tayeh, Marwan K.
Rupani, Amit R.
Innis, Jeffrey W.
Mantzoros, Christos S.
Conjeevaram, Hari S.
Metadata
Show full item record
Abstract
Background: Recombinant leptin therapy reverses nonalcoholic steatohepatitis (NASH) in leptin-deficient lipodystrophy. We inquired if leptin therapy would improve NASH in more common forms of this heterogeneous condition.
URI
http://hdl.handle.net/20.500.12627/176264
https://doi.org/10.1016/j.medj.2021.04.001
Collections